NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
16 May 2025
| Name: | SOMNOMED LIMITED (SOM) |
| ISIN: | AU000000SOM1 |
| Date of Listing: | 27 August 2004 |
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 003 255 221ABN: 35 003 255 221
Registration Date: 16 March 1987
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of SomnoMed Limited will be lifted immediately following the release by SOM of an announcement regarding the results of the institutional component of an accelerated non-renounceable entitlement offer and having noted SOM's prior announcement on Tuesday 9 April 2024 of a trading update and changes to its earnings guidance for the financial year ending 30 June 2024. | 10/04/2024 |
The company has successfully completed the institutional component of its 1 for 1.01 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The Institutional Entitlement Offer closed on Tuesday, 9 April 2024. | 10/04/2024 |
The company releases a notice of proposed issue of securities. | 09/04/2024 |
The company releases an Investor Presentation. | 09/04/2024 |
The company releases a prospectus for a pro-rata accelerated non-renounceable entitlement offer to Eligible Shareholders of approximately 107.5 million New Shares at an issue price of $0.21 per New Share on the basis of 1 New Shares for every 1.01 Shares held on the Record Date to raise approximately $22.6 million before expenses. The Retail Entitlement Offer closes at 5.00pm AEST on Wednesday, 1 May 2024 (unless extended). Valid acceptances must be received before that date. | 09/04/2024 |
Revised financial year ending 30 June 2024 (FY24) revenue growth guidance of 6% - 9%, versus previous guidance of 12%+, related to inability to meet customer demand due to manufacturing capacity constraints. Revised FY24 EBITDA1 guidance of $(1) - $0 million, versus previous guidance of $3 million+, due to manufacturing constraints and delayed implementation of cost initiatives announced in January 2024. FY24 capex guidance of $5 million, unchanged from previous guidance. SomnoMed is launching a fully underwritten $22.6 million capital raising to clean its balance sheet and reduce costs, and fund investment into manufacturing capacity initiatives and Rest Assure scalability. | 09/04/2024 |
SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer. | 05/04/2024 |
SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer. | 05/04/2024 |
The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding trading update and earning guidance. | 02/04/2024 |
The suspension of trading in the securities of SomnoMed Limited will be lifted immediately, following the release by SOM of an announcement regarding details of a capital raise and updated guidance. | 26/03/2020 |
The company announces the successful completion of the institutional component of its 1 for 3.24 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The institutional entitlement offer closed on Wednesday, 25 March 2020. The shortfall from the institutional entitlement offer has been placed to TDM Growth Partners Pty Ltd as well as certain existing institutional shareholders of the company and new institutional investors pursuant to a bookbuild. The retail component of the entitlement offer will raise up to a further approximately $5.8 million. | 26/03/2020 |
The company releases a cleansing notice in relation to its entitlement issue. | 25/03/2020 |
The company releases a notice of Proposed issue of Securities - SOM. | 25/03/2020 |
The company releases an Investor Presentation. | 25/03/2020 |
SomnoMed Limited provides a trading update with regard to the impact of Coronavirus (COVID 19) on the business. SomnoMed con-currently announces a 1 for 3.24 fully underwritten accelerated pro-rata non-renounceable entitlement offer to raise gross proceeds of approximately $15.5 million. | 25/03/2020 |
The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding details of a capital raise and updated guidance. | 19/03/2020 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 27/11/2009 |
listed entity carried for record purposes only | 05/11/2004 |
this company was previously Indo Pacific Securities Limited, delisted following closure of Second Board market in 1992 | 05/11/2004 |
The suspension of trading in the securities of SomnoMed Limited will be lifted immediately following the release by SOM of an announcement regarding the results of the institutional component of an accelerated non-renounceable entitlement offer and having noted SOM's prior announcement on Tuesday 9 April 2024 of a trading update and changes to its earnings guidance for the financial year ending 30 June 2024. | 10/04/2024 |
The company has successfully completed the institutional component of its 1 for 1.01 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The Institutional Entitlement Offer closed on Tuesday, 9 April 2024. | 10/04/2024 |
The company releases a notice of proposed issue of securities. | 09/04/2024 |
The company releases an Investor Presentation. | 09/04/2024 |
The company releases a prospectus for a pro-rata accelerated non-renounceable entitlement offer to Eligible Shareholders of approximately 107.5 million New Shares at an issue price of $0.21 per New Share on the basis of 1 New Shares for every 1.01 Shares held on the Record Date to raise approximately $22.6 million before expenses. The Retail Entitlement Offer closes at 5.00pm AEST on Wednesday, 1 May 2024 (unless extended). Valid acceptances must be received before that date. | 09/04/2024 |
Revised financial year ending 30 June 2024 (FY24) revenue growth guidance of 6% - 9%, versus previous guidance of 12%+, related to inability to meet customer demand due to manufacturing capacity constraints. Revised FY24 EBITDA1 guidance of $(1) - $0 million, versus previous guidance of $3 million+, due to manufacturing constraints and delayed implementation of cost initiatives announced in January 2024. FY24 capex guidance of $5 million, unchanged from previous guidance. SomnoMed is launching a fully underwritten $22.6 million capital raising to clean its balance sheet and reduce costs, and fund investment into manufacturing capacity initiatives and Rest Assure scalability. | 09/04/2024 |
SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer. | 05/04/2024 |
SomnoMed requests that trading in its securities continue to be suspended whilst it prepares a proposed equity capital raising which is proposed to comprise an accelerated entitlement offer as well as to finalise a trading update and a downgrade to the Company's FY24 guidance. "¢ SomnoMed expects that it will announce any Entitlement Offer and revised FY24 guidance on Tuesday 9 April 2024 but requests that the voluntary suspension remain in place until the first to occur of the commencement of normal trading on Wednesday 10 April 2024 and the release of an announcement in relation to the outcome of the institutional component of any Entitlement Offer. | 05/04/2024 |
The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding trading update and earning guidance. | 02/04/2024 |
The suspension of trading in the securities of SomnoMed Limited will be lifted immediately, following the release by SOM of an announcement regarding details of a capital raise and updated guidance. | 26/03/2020 |
The company announces the successful completion of the institutional component of its 1 for 3.24 accelerated non-renounceable entitlement offer of new fully paid ordinary shares in the company. The institutional entitlement offer closed on Wednesday, 25 March 2020. The shortfall from the institutional entitlement offer has been placed to TDM Growth Partners Pty Ltd as well as certain existing institutional shareholders of the company and new institutional investors pursuant to a bookbuild. The retail component of the entitlement offer will raise up to a further approximately $5.8 million. | 26/03/2020 |
The company releases a cleansing notice in relation to its entitlement issue. | 25/03/2020 |
The company releases a notice of Proposed issue of Securities - SOM. | 25/03/2020 |
The company releases an Investor Presentation. | 25/03/2020 |
SomnoMed Limited provides a trading update with regard to the impact of Coronavirus (COVID 19) on the business. SomnoMed con-currently announces a 1 for 3.24 fully underwritten accelerated pro-rata non-renounceable entitlement offer to raise gross proceeds of approximately $15.5 million. | 25/03/2020 |
The securities of SomnoMed Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of SOM, pending the release of an announcement regarding details of a capital raise and updated guidance. | 19/03/2020 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 27/11/2009 |
listed entity carried for record purposes only | 05/11/2004 |
this company was previously Indo Pacific Securities Limited, delisted following closure of Second Board market in 1992 | 05/11/2004 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 05/12/2024 | Guy Russo | 665,000 | $0.443 | $294,662 |
| 23/09/2024 | Karen Borg | 12,238 | $0.440 | $5,385 |
| 09/09/2024 | Karen Borg | 25,593 | $0.420 | $10,749 |
| 28/02/2023 | Amrita Blickstead | 28,359 | $1.148 | $32,567 |
| 23/09/2022 | Hamish Corlett | 130,094 | $1.380 | $179,530 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Guy Russo | Chairman | 24/08/2020 |
| Ye-Fei Guo | CFO | 27/11/2024 |
| Darren Collins | CFO | 01/08/2023 |
| Karen Borg | Executive Director, CEO | 26/11/2020 |
| Amrita Blickstead | Executive Director, CEO | 24/08/2020 |
| Andrew Price | Director | 17/01/2025 |
| Michael Gordon | Director | 24/08/2020 |
| Ben Gisz | Director | 08/10/2024 |
| Terence Flitcroft | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Hamish Corlett | Director | 01/05/2018 | 08/10/2024 |
| Neil Verdal-Austin | Managing Director, CEO | 15/10/2008 | 23/02/2024 |
| Hilton Brett | Non Exec Director | 24/08/2020 | 12/10/2023 |
| Herve Fievet | CFO | 08/04/2019 | 05/07/2023 |
| Peter Neustadt | Non Exec Chairman | 13/11/2006 | 24/08/2020 |
| Lee Ausburn | Non Exec Director | 15/09/2011 | 24/08/2020 |
| Robert Scherini | Non Exec Director | 15/09/2011 | 24/08/2020 |
| Derek Smith | CEO | 01/09/2016 | 16/11/2018 |
| Ralf Barschow | CEO | 11/07/2007 | 31/07/2012 |
| Graham Hurst | Non Exec Director | 09/06/2006 | 05/04/2012 |
| Paul Hopper | Non Exec Director | 01/07/2007 | 30/09/2011 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
